Mink Therapeutics Inc (INKT) Stock Price, Quote & News

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilim...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 994 8250

Website: minktherapeutics.com

Address:

149 Fifth Avenue, Suite 500, New York, United States

2_logs_higher Apr. 20 at 2:13 PM

$AGEN & $INKT Agenus announces Phase II results from gastroesophageal cancer therapy Patients received induction with agenT-797 (alone or with BOT/BAL) or started the combination without induction. Salong Debbarma April 20, 2026 https://www.clinicaltrialsarena.com/news/agenus-gastroesophageal-cancer-therapy-results/

1 · Reply

2_logs_higher Apr. 20 at 2:10 PM

$INCY & $INKT Agenus announces Phase II results from gastroesophageal cancer therapy Patients received induction with agenT-797 (alone or with BOT/BAL) or started the combination without induction. April 20, 2026 https://www.clinicaltrialsarena.com/news/agenus-gastroesophageal-cancer-therapy-results/

0 · Reply

Outcomes Apr. 20 at 1:51 PM

$IBRX ....$INKT down 🤔

0 · Reply

Guptasulo Apr. 20 at 12:11 PM

$INKT $AGEN $IBRX Why Bullish? Trial had 3 arms (A, B, C), total n=17 Median OS: Arms A + B = 9.5 months Arm C = 5.2 months Design matters: Arm A: INKT-797 priming then BOT/BAL + chemo (week 3) Arm B: INKT-797 + BOT/BAL then chemo (week 3) Arm C: INKT-797 + BOT/BAL + chemo all upfront at one go. Key insight: timing of chemo vs immune priming From prior MiNK Therapeutics Phase 1 INKT-797 study: INKT-797 alone gave SOC-like outcomes relate this to ArmA INKT-797 + BOT/BAL produced 23 months median OS (signal) (relate this to Arm B) Interpretation: Arm B likely strongest (immune activation first, chemo later) Arm A moderate (delayed combo) Arm C weakest (chemo upfront may blunt immune priming) INKT-797 works by immune reprogramming, not direct tumor kill Giving chemo too early may counteract that mechanism Bottom line: The signal is about sequencing that yields survivability results.

0 · Reply

Biotechguy21 Apr. 20 at 11:06 AM

$AGEN $IBRX $INKT the bigger picture is who runs these companies and how they have been failing SHs for years 💩💩💩💩

0 · Reply

Turnthemachinesbackon Apr. 20 at 7:02 AM

$INKT GROK says buy more and hold.

0 · Reply

Guptasulo Apr. 20 at 5:26 AM

$INKT $AGEN $IBRX Anyone focused on ORR is missing the bigger picture. “The study did not meet ORR; however…” that “however” is doing the heavy lifting. ORR = tumor shrinkage. (The term Overall Response Rate can be misleading — it reflects shrinkage, not survival.) Not survival. Not durability. Not cure. Even CRs can relapse ~50%+ in refractory settings. So ORR >30% does not mean “best treatment.” What actually matters here: 43% alive at 12 AND 18 months - flat plateau (This is important) OS 9.5 months vs 5–8 months SOC (Signal mainly from Arm A and Arm B (2/3 of the patients) HR 0.19 - significant risk reduction That is not typical chemo behaviour. MiNK’s approach: Focused on immune reprogramming, not just tumor kill Targets the tumor microenvironment and immune memory (durability). This is an excellent outcome. “Tumor shrinkage is short-term. Survival is what counts.” This matters most to doctors, caregivers and patients. Mink has it unlike any other.

0 · Reply

BenUnknown Apr. 20 at 1:27 AM

$INKT Looks like it will be a sell the news day tomorrow…

0 · Reply

Tigertkbc Apr. 17 at 9:42 PM

$INKT So not meeting ORR is entirely related to Inkt?

0 · Reply

BenUnknown Apr. 17 at 8:26 PM

$INKT interesting survival signals. Bummer they missed the ORR. Curious to see how investors / share price react

3 · Reply

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

Apr 1, 2026, 7:30 AM EDT - 19 days ago

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

Mar 31, 2026, 7:30 AM EDT - 20 days ago

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

Mar 17, 2026, 7:30 AM EDT - 4 weeks ago

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

Mar 11, 2026, 9:24 AM EDT - 5 weeks ago

Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?

Mar 10, 2026, 9:47 AM EDT - 5 weeks ago

MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally

Mar 10, 2026, 5:30 AM EDT - 5 weeks ago

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

Feb 3, 2026, 9:30 PM EST - 2 months ago

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

Jan 8, 2026, 12:00 PM EST - 3 months ago

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

Nov 20, 2025, 11:42 AM EST - 5 months ago

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

$MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025$

Nov 7, 2025, 9:00 AM EST - 5 months ago

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Sep 29, 2025, 7:30 AM EDT - 7 months ago

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

Sep 25, 2025, 7:30 AM EDT - 7 months ago

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

Sep 18, 2025, 7:30 AM EDT - 7 months ago

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

Aug 14, 2025, 7:30 AM EDT - 8 months ago

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Jul 31, 2025, 8:30 AM EDT - 9 months ago

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

Jul 15, 2025, 8:21 AM EDT - 9 months ago

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Jul 11, 2025, 12:33 PM EDT - 10 months ago

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?

Jun 10, 2025, 1:33 PM EDT - 11 months ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Jun 2, 2025, 9:29 AM EDT - 11 months ago

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

May 15, 2025, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

Mar 18, 2025, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Mar 4, 2025, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:30 AM EST - 1 year ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 1 year ago

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Jan 23, 2025, 2:13 PM EST - 1 year ago

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Dec 18, 2024, 9:45 AM EST - 1 year ago

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Nov 11, 2024, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

Nov 7, 2024, 10:00 AM EST - 1 year ago

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

Oct 31, 2024, 9:15 AM EDT - 1 year ago

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

Oct 8, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

Oct 4, 2024, 9:10 AM EDT - 1 year ago

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Second Quarter 2024 Results and Business Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

Jul 31, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

May 22, 2024, 7:30 AM EDT - 2 years ago

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 14, 2024, 7:30 AM EDT - 2 years ago

MiNK Reports First Quarter 2024 Results

May 13, 2024, 7:30 AM EDT - 2 years ago

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

Apr 30, 2024, 7:30 AM EDT - 2 years ago

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

Apr 8, 2024, 12:00 PM EDT - 2 years ago

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Mar 21, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 7, 2024, 7:30 AM EST - 2 years ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 6, 2024, 8:30 AM EST - 2 years ago

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

$MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene$

Jan 30, 2024, 8:00 AM EST - 2 years ago

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Dec 20, 2023, 7:30 AM EST - 2 years ago

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Nov 9, 2023, 7:00 AM EST - 2 years ago

MiNK Therapeutics Reports Third Quarter 2023 Results

Nov 3, 2023, 12:00 PM EDT - 2 years ago

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Oct 30, 2023, 8:00 AM EDT - 2 years ago

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

Sep 27, 2023, 9:05 AM EDT - 2 years ago

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

2_logs_higher Apr. 20 at 2:13 PM

1 · Reply

2_logs_higher Apr. 20 at 2:10 PM

0 · Reply

Outcomes Apr. 20 at 1:51 PM

$IBRX ....$INKT down 🤔

0 · Reply

Guptasulo Apr. 20 at 12:11 PM

0 · Reply

Biotechguy21 Apr. 20 at 11:06 AM

$AGEN $IBRX $INKT the bigger picture is who runs these companies and how they have been failing SHs for years 💩💩💩💩

0 · Reply

Turnthemachinesbackon Apr. 20 at 7:02 AM

$INKT GROK says buy more and hold.

0 · Reply

Guptasulo Apr. 20 at 5:26 AM

0 · Reply

BenUnknown Apr. 20 at 1:27 AM

$INKT Looks like it will be a sell the news day tomorrow…

0 · Reply

Tigertkbc Apr. 17 at 9:42 PM

$INKT So not meeting ORR is entirely related to Inkt?

0 · Reply

BenUnknown Apr. 17 at 8:26 PM

$INKT interesting survival signals. Bummer they missed the ORR. Curious to see how investors / share price react

3 · Reply

Goodstockday Apr. 17 at 7:36 PM

$INKT These results are not great. Specific OS data not reported. Need more information, but they seem to be hiding big stuff.

0 · Reply

Spartrap Apr. 17 at 7:35 PM

$INKT great data in the induction arms! (meaning the 2 arms that had their first cycle begin with an agenT-797 and/or Boat+bal induction) So this validates the immune priming thesis. "Median overall survival (OS) was 9.5 months in the induction cohort versus 5.2 months without induction, with 43% of induction-treated patients alive at both 12 and 18 months, compared with 20% and 0%, respectively, in the non-induction cohort." The survival difference is huge. Sadly the Overall Response Rate didn't meet the criteria so the data is not so easy to interpret from the market standpoint - the way forward isn't as straightforward as when the primary endpoint is met

0 · Reply

pedmac2000 Apr. 17 at 7:33 PM

$INKT what the better buy Agenus or mink?

1 · Reply

Doom_Gloom_AR Apr. 17 at 7:15 PM

$AGEN still time to buy the $INKT data https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-reports-phase-ii-data-immune-reprogramming-and

0 · Reply

Doom_Gloom_AR Apr. 17 at 7:10 PM

$INKT Home run! .19 HR !! 6.9mos!

0 · Reply

Tigertkbc Apr. 17 at 7:02 PM

$INKT What was that??

0 · Reply

BenUnknown Apr. 17 at 6:20 PM

$INKT added again👊🏼🥂

0 · Reply

uptrend2025 Apr. 17 at 5:55 PM

$INKT Cancer presentation this weekend 👀

1 · Reply

Spartrap Apr. 17 at 3:01 PM

$INKT AACR this weekend, with news in Gastric Cancer, 2 years worth of data, n=37, solid mechanistic rationale, very interesting study in combo with $AGEN drugs. https://clinicaltrials.gov/study/NCT06251973?term=Agent-797&viewType=Card&rank=4

2 · Reply

ghcb1981 Apr. 17 at 12:56 PM

$INKT

0 · Reply

janed102 Apr. 17 at 12:08 PM

$INKT $IBRX

0 · Reply

ghcb1981 Apr. 17 at 9:30 AM

$INKT

0 · Reply

Market Cap	70.57M
Revenue (ttm)	0.00
Net Income (ttm)	-12.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	91,000
Avg Vol	369,484
Day's Range	N/A - N/A
Shares Out	4.97M
Stochastic %K	48%
Beta	0.35
Analysts	Strong Sell
Price Target	$39.00